Related Experiment Video
Updated: Jun 13, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Predicting the response of CML patients to tyrosine kinase inhibitor therapy
Deborah L White1, Timothy P Hughes
1Division of Haematology, SA Pathology IMVS/RAH Campus, Frome Road, Adelaide, South Australia, Australia. Deb.white@imvs.sa.gov.au
Abstract:
Tyrosine kinase inhibitor (TKI) therapy has significantly changed the treatment paradigm for patients with chronic myeloid leukemia (CML). The first-generation inhibitor, imatinib, has demonstrated remarkable efficacy in most chronic-phase patients. Disease progression remains a significant risk for the first 2 to 3 years of TKI therapy, but the risk falls significantly thereafter. Early recognition of each individual's risk of progression may facilitate a customized approach to TKI therapy. Using such an approach, drug selection and treatment intensity would be adjusted on the basis of each patient's disease profile. Currently available prognostic indicators have limited value in the setting of the potent kinase inhibition afforded by TKIs. Furthermore, these indicators provide little guidance regarding optimal drug choice and dose intensity. In the future, assays that directly assess the efficacy of the protein-drug interaction, taking into account factors intrinsic to the patient and the amount of drug freely available in the plasma, are likely to be of greater value.
Insights
Tyrosine kinase inhibitor (TKI) therapy transformed chronic myeloid leukemia (CML) treatment. Personalized TKI therapy, guided by early risk assessment, can optimize drug selection and intensity for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Tyrosine kinase inhibitor (TKI) therapy, notably imatinib, has revolutionized chronic myeloid leukemia (CML) treatment.
- While effective, CML patients face a significant risk of disease progression in the initial years of TKI therapy.
Purpose of the Study:
- To explore the need for individualized risk assessment in TKI therapy for CML.
- To highlight the limitations of current prognostic indicators in guiding personalized TKI treatment strategies.
Main Methods:
- Review of current TKI therapy efficacy and progression risks in CML.
- Analysis of the inadequacy of existing prognostic markers for TKI treatment optimization.
Main Results:
- Disease progression risk is highest in the first 2-3 years of TKI therapy, decreasing significantly afterward.
- Current prognostic indicators offer limited value in tailoring TKI drug choice and dose intensity.
Conclusions:
- Early identification of individual CML patient risk can enable customized TKI therapy approaches.
- Future research should focus on assays assessing protein-drug interaction efficacy, considering patient-specific factors and drug availability, for improved treatment personalization.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...